GSK set to escape Chinese corruption charges, execs to be hit

Authorities in China are reportedly likely to charge some GlaxoSmithKline (GSK) executives in the country with corruption but not the company itself.

Police are investigating allegations that GSK paid up to 3B yuan ($492M) to travel agencies to facilitate bribes to doctors and officials in order to boost drug sales.

Criminal charges against GSK would be particularly serious, and could result in hefty fines, disruptions to operations and even the withdrawal of the company's business license. However, it's very rare for the government to indict companies.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs